NCT00419159View on ClinicalTrials.gov

Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

199

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Colorectal Cancer
Interventions
DRUG

Everolimus (RAD001)

Everolimus was supplied in 5 mg tablets in blister packs.

Trial Locations (1)

89135

Nevada Cancer Institute, Las Vegas

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY